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Abstract
Although probiotics and antibiotics have been used for decades as growth promoters in animals, attention has only recently been drawn to
the association between the gut microbiota composition, its manipulation, and obesity. Studies in mice have associated the phylum Firmicutes
with obesity and the phylum Bacteroidetes with weight loss. Proposed mechanisms linking the microbiota to fat content and weight include
differential effects of bacteria on the efﬁciency of energy extraction from the diet, and changes in host metabolism of absorbed calories. The
independent effect of the microbiota on fat accumulation has been demonstrated in mice, where transplantation of microbiota from obese
mice or mice fed western diets to lean or germ-free mice produced fat accumulation among recipients. The microbiota can be manipulated
by prebiotics, probiotics, and antibiotics. Probiotics affect the microbiota directly by modulating its bacterial content, and indirectly through
bacteriocins produced by the probiotic bacteria. Interestingly, certain probiotics are associated with weight gain both in animals and in
humans. The effects are dependent on the probiotic strain, the host, and speciﬁc host characteristics, such as age and baseline nutritional
status. Attention has recently been drawn to the association between antibiotic use and weight gain in children and adults. We herein
review the studies describing the associations between the microbiota composition, its manipulation, and obesity.
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Introduction
Ten trillion to 100 trillion (1014) microorganisms populate the
adult intestines [1,2]. The vast majority reside in the colon,
where densities approach 1011–1012 cells/mL. Almost all of
these organisms are bacteria, and a minority are archaeons,
eukaryotes, and viruses [3,4]. Bacteria are classiﬁed from the
phylum to species level (Table 1). The two most abundant
bacterial phyla in humans and in mice are the Firmicutes (60–
80%) and the Bacteroidetes (20–40%) [1,3,5]. Most of the
representatives of these two phyla do not grow outside of their
host [1]. Babies acquire their initial microbiota from the
surrounding ecosystems, especially the maternal vaginal and
faecal microﬂora [2,6], and the human gut microbiome is shared
among family members [7,8]. The gut microbiota composition
depends on age, sex, geography, ethnicity, family, and diet, and
can be modulated by prebiotics, probiotics, and antibiotics.
Microbial changes in the human gut were proposed as a
possible cause of obesity [5,9,10]. Certain phyla and classes of
bacteria are associated with improved transfer of calories from
the diet to the host, and with changes in the host metabolism of
absorbed calories [11]. Gut microorganisms ferment dietary
polysaccharides intomonosaccharides and short-chain fatty acids,
and thus allow the extraction of calories from indigestible dietary
polysaccharides. One of the ways in which they affect host
metabolism is by suppressing fasting-induced adipocyte factor,
which is a lipoprotein lipase inhibitor, and the suppression of
which contributes to the deposition of triglycerides in adipocytes.
The Association between Microbiota
Composition and Obesity
Studies in mice have found a higher abundance of Firmicutes in
obese mice and those fed on western diets, concomitant with
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a decrease in the abundance of Bacteroidetes [1,11]. Within the
phylum Firmicutes, the class Mollicutes was the most common in
obese mice [11]. Bacteroidetes possess fewer genes for
enzymes involved in lipid and carbohydrate metabolism than
Firmicutes [12]. However, within the phylum Bacteroidetes,
Bacteroides thetaiotaomicron was found to improve host nutri-
ent absorption and processing [13].
Studies in humans found various Firmicutes/Bacteroidetes
ratios in obese individuals. Some supported the ﬁnding of a
high Firmicutes/Bacteroidetes ratio [5,14–16], some did not ﬁnd
a correlation between body mass index and the Firmicutes/
Bacteroidetes ratio [3,17], and still others found an opposite
ratio [18,19]. Turnbaugh et al. [7] described a lower propor-
tion of Bacteroidetes and a higher proportion of Actinobacteria in
obese than in lean individuals, with no signiﬁcant difference in
the proportion of Firmicutes. A signiﬁcantly higher level of
Lactobacillus species (from the phylum Firmicutes) was found in
obese patients than in lean controls [14]. Speciﬁcally, a higher
level of Lactobacillus reuteri and lower levels of Lactobacillus
casei/paracasei and Lactobacillus plantarum were associated with
obesity [15]. Reduced proportions of butyrate-producing
Firmicutes were described in obese subjects on weight loss
diets [20] and their presence was lower in obese subjects as
compared with their blood-related lean family members [8].
Another bacterial genus that has been implicated in obesity
is Biﬁdobacterium (belonging to the phylum Actinobacteria).
Several studies in humans found an association between lower
levels of biﬁdobacteria and obesity [15,16,18,19,21]. Biﬁdo-
bacteria were found at higher levels in the intestinal microbiota
of breast-fed infants than in that of formula-fed infants [12].
The association between biﬁdobacteria and obesity is probably
also species-speciﬁc [22].
At the species level, several studies have investigated the
association between speciﬁc bacterial species and obesity in
humans. An association between Staphylococcus aureus and an
overweight state was demonstrated in children and pregnant
women [19,21]. Reduced numbers of Bacteroides and increased
numbers of Staphylococcus, Enterobacteriaceae and Escherichia
coli have been described in overweight as compared with
normal-weight pregnant women [16]. Levels of Faecalibacteri-
um prausnitzii (of the phylum Firmicutes) were signiﬁcantly
higher in obese than in non-obese children [23]. The
proportions of the Bacteroides–Prevotella group were shown
to increase after weight loss in obese adolescents [24]. The
latter study also revealed a correlation between reductions in
Clostridium histolyticum and Eubacterium rectale–Clostridium coc-
coides (Firmicutes) proportions and weight loss.
Turnbaugh et al. [25] demonstrated more environmental
gene tags of archaeons in the caecal microbiome of obese mice
than in that of lean mice. Archaeons are methanogenic
organisms that increase the efﬁciency of bacterial fermenta-
tion. The principal methanogenic archaeon in the human gut is
Methanobrevibacter smithii. Studies in mice colonized with this
organism and/or B. thetaiotaomicron revealed that co-coloniza-
tion increases the efﬁciency of polysaccharide fermentation,
leading to an increase in adiposity as compared with mice
colonized with either organism alone [25,26]. Zhang et al. [27]
found that Methanobacteriales were present only in obese
individuals, after studying three obese individuals and three
human controls. Several other studies in humans have
demonstrated lower levels of Methanobrevibacter in overweight
and obese human volunteers [14,15,18].
Microbiota Transplantation Studies
The independent contribution of the microbiota to fat
accumulation has been demonstrated in a series of elegant
in vivo studies in mice. Germ-free mice, lacking a microbiota,
have signiﬁcantly less body fat than normal mice, despite eating
more [10]. Transfer of the microbiota from normal to germ-
free mice caused a signiﬁcant increase in body fat content.
Transplanting germ-free mice with the microbiota from obese
mice led to a signiﬁcantly increased fat content as compared
with transplantation of the microbiota from lean mice, and this
was associated with a greater relative abundance of Firmicutes
in the guts of both the obese donors and their recipients [25].
This was observed in controlled conditions, where both
groups had the same baseline weight and received the same
amount of feeding. Transplanting germ-free mice with the
microbiota from mice raised on a western diet led to
signiﬁcantly increased body fat as compared with mice
transplanted with the microbiota from donors who had been
fed a lean low-fat diet, rich in structurally complex plant
polysaccharides [11]. Both carbohydrate restriction and fat
restriction from the western diet prevented the increased
accumulation of fat in recipients. This was accompanied by a
decrease in the presence of the Mollicutes lineage (phylum
Firmicutes) and an increase in the relative abundance of
Bacteroidetes. Turnbaugh et al. [28] successfully colonized mice
with human faeces, and fed them with the western diet vs. the
TABLE 1. Examples of the classiﬁcation of several common
gut bacteria
Domain Bacteria Bacteria Bacteria Bacteria
Phylum Firmicutes Firmicutes Bacteroidetes Actinobacteria
Class Clostridia Bacilli Bacteroidetes Actinobacteria
Order Clostridiales Lactobacillales Bacteroidiales Biﬁdobacteriales
Family Clostridiaceae Lactobacillaceae Bacteroidiaceae Biﬁdobacteriaceae
Genus Clostridium Lactobacillus Bacteroides Biﬁdobacterium
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low-fat/plant polysaccharide-rich diet for 2 weeks, and then
transplanted their microbota into germ-free mice. Germ-free
mice receiving the microbiota from the obese western-diet-fed
humanized mice gained signiﬁcantly more adiposity than the
mice receiving the microbiota from the low-fat-fed humanized
mice. Again, this was achieved despite matching of the two
groups of recipients by age, weight, and body fat, similar
feeding of recipients with low-fat/plant polysaccharide-rich
diets, and similar consumption of food. Different strains of
Biﬁdobacterium (phylum Actinobacteria) from human volunteers’
fresh faeces given to mice produced different effects on body
weight [22]. In all studies, the time to fat changes following
microbiota manipulation was up to 2 weeks.
These studies prove that the microbiota by itself can cause
weight gain. Themicrobiota derived from genetically obesemice
or mice rendered obese by diet can cause fat accumulation, and
this is not mediated by increased food consumption. The studies
also showed that this is mediated both by improved efﬁciency of
transfer of calories from the diet to the host and through effects
on host metabolism of the absorbed calories [11].
Association betweenDiet and theMicrobiota
Dietary habits constitute a major factor inﬂuencing the
diversity of the human gut microbiota [29]. A vegetarian diet
is known to affect the intestinal microbiota by decreasing the
amount and modifying the diversity of Clostridium cluster IV
and Clostridium rRNA clusters XIVa and XVIII [30,31]. Walker
et al. [32] successively tested obese individuals with a control
diet, a diet high in resistant starch or non-starch polysaccha-
rides, and a reduced-carbohydrate weight loss diet. There was
no signiﬁcant effect of diet on the proportions of the four main
phyla represented in the gut microbiota. E. rectale and
Ruminococcus bromii showed dramatically increased propor-
tions in individuals receiving the resistant starch diet, whereas
the proportion of Collinsella aerofaciens-related sequences was
decreased signiﬁcantly in those receiving the weight loss diet.
Gut analysis of African children from Burkina Faso showed
speciﬁc abundance of Prevotella, Xylanibacter and Treponema
containing bacterial genes for cellulose and xylan hydrolysis,
which are completely absent in European children, and are
probably linked to high intake of ﬁbre, allowing increased
extraction of metabolic energy from the polysaccharides of
ingested plants [33]. Wu et al. [34] found that enterotypes
were strongly associated with long-term diets. After short-
term diet modiﬁcation, the gut microbiota alteration occurred
rapidly and was quickly reversible [32,34]. Conversely, persis-
tent modiﬁcations of individual enterotypes occurred during
long-term dietary interventions [34]. Finally, a high-fat diet can
be responsible for Proteobacteria abundance (order Desulfovib-
rio), but authors comparing the gut ﬂora of malnourished
children with that of well-nourished children in Bangladesh
found a Bacteroidetes decrease and a Proteobacteria increase,
notably for Escherichia coli and Klebsiella spp. [35].
The Inﬂuence of Prebiotics on theMicrobiota
Prebiotics are deﬁned as food ingredients that stimulate the
growth of a limited number of microbial genus/species in the
gut microbiota that are hypothesized to confer health beneﬁts
to the host. The administration of oligofructose to high-fat-fed
mice increased the abundance of Biﬁdobacterium and normal-
ized endotoxaemia and the inﬂammatory tone associated with
the high-fat diet [36]. The administration of oligofructose to
genetically obese mice induced increases in the levels of
Lactobacillus, Biﬁdobacterium, and C. coccoides–E. rectale, which
led to a reduction in intestinal permeability and an improve-
ment in tight junction integrity and inﬂammatory markers, such
as lipopolysaccharides and cytokines [37].
The Inﬂuence of Probiotics on theMicrobiota
and Obesity
Probiotics are live bacteria that are thought to bebeneﬁcial to the
host. The ﬁrst food containing probiotics ingested by humans is
breast milk. Two studies showed that Biﬁdobacterium, Lactobacil-
lus and Enterococcus strains showed identical random ampliﬁca-
tion of polymorphic DNA proﬁles in breast milk samples and
faecesof newborns at different sampling times, suggesting vertical
transfer of these bacteria from the mother’s milk to the infant
[38,39]. The inﬂuence of probiotics on the intestinal ﬂora is highly
dependent on their adhesion to colonocytes, resistance to acidic
pH, and bile salt tolerance [40]. In an interventional study,
L. reuteri DSM 12246 was associated with excellent adhesion. In
contrast, Lactobacillus delbrueckii ssp. lactis CHCC2329 did not
survive at pH 2.5, andwas found in only a fewof those towhom it
was administered. It is plausible that probiotics modulate and
shape the digestive microbiota according to the antibiotic
spectrum of their bacteriocins, which are antibiotic-like sub-
stances produced by bacteria.
To date, the metagenomic data available from human
intervention studies with probiotics are very limited [41].
Recently, gut analysis was performed by ﬂow cytometry and
ﬂuorescence in situ hybridization in newborns’ faecal samples
after administration of probiotics vs. placebo to mothers for
2 months before delivery up to 2 months after delivery
(during breast-feeding) in a Finish cohort, or to newborns
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receiving formula feeding from 1 month of age up to 4 months
of age in a German cohort of newborns [42]. The probiotics
used included Lactobacillus rhamnosus LPR, Lactobacillus paraca-
sei ST11 (only in the Finish cohort), and Biﬁdobacterium longum
BL999. The combination of L. rhamnosus LPR and Biﬁdobacte-
rium longum BL999 had the effect of raising the level of
Lactobacillus–Enterococcus and lowering the level of Biﬁdobacte-
rium in the gut microbiota of the Finnish cohort (whose
mothers were treated), whereas there was no such effect in
the German cohort (where infants were given probiotics). The
authors concluded that probiotic treatment had different
impacts on the gut microbiota composition in Finnish and
German infants, owing to differences in mode of feeding and
the early commensal microbiota. The speciﬁcity of the
Lactobacillus species or strain for its effect on the gut
microbiota was demonstrated in this study.
Probiotics, which had also been used for decades in
agriculture for their growth-promoting effects, have undergone
a revival since the ban on antibiotics as growth promoters in
Europe from 1 January 2006 [43]. Probiotics are also frequently
used by people for their proposed health beneﬁts. We
performed a meta-analysis on the effects of probiotics on
weight in humans and animals [44]. The bacteria most
commonly used belonged to the genera Lactobacillus, Biﬁdobac-
terium, Enterococcus, and Streptococcus. Lactobacillus acidophilus,
Lactobacillus fermentum and Lactobacillus ingluviei were associ-
ated with a weight gain effect in lean individuals, whereas
L. plantarum and Lactobacillus gasseri strains had an anti-obesity
effect in overweight/obese people. It is most likely that this
effect was dependent on the strain used and the metabolic
phenotype of the host, as we found one study linking L. gasseri
ATCC 4962 and ATCC 4963 (formerly named L. acidophilus)
with weight gain in bottle-fed infants, in contrast to the results
observed in overweight/obese people. In a randomized con-
trolled trial, individuals randomized to receive fermented milk
containing L. gasseri showed reductions in abdominal adiposity,
body weight, and other measures [45]. Whether the same
Lactobacillus strains could have a growth-promoting effect in
undernourished individuals and an anti-obesity effect in obese
individuals needs to be clariﬁed. Overall, both the probiotic
bacterial strain and the host are important determinants of the
effects of probiotics on obesity, and it is possible that certain
marketed probiotics favour obesity.
TheInﬂuenceofAntibioticson theMicrobiota
Oral and intravenous antibiotics have been reported to
decrease the bacterial load in the digestive tract [46,47],
although other studies have found that only the microbiota
composition is changed [48]. For example, metronidazole,
cefoperazone, or vancomycin, in contrast to amoxycillin, led to
alterations in community structure without a signiﬁcant
decrease in the overall bacterial biomass [49]. Studies
summarizing the effects of antibiotics on the gut microbiota
in animals are summarized in Table 2. Antibiotic effects can be
species-speciﬁc. Lactobacillus appears to be particularly
impacted by growth-promoting antibiotics in animal studies
[50]. In contrast, the levels of some bacterial genera seem to
be reduced by the growth-promoting antibiotics, particularly
Proteobacteria (e.g. Salmonella) [51]. Finally, whereas rapid
recovery has been described after short-term antibiotic
TABLE 2. In vivo studies examining the effects of antibiotics on microbiota
Reference Host Antibiotics Microbiota changes with antibiotics Other effects
Cho, 2012 [50] Mice Subtherapeutic antibiotic
treatment with vancomycin,
penicillin, and chlortetracyclines
Proportion of Firmicutes higher vs. controls
Lachnospiraceae family increased
Subtherapeutic antibiotic treatment
altered the gene counts of genes
involvedin the metabolism of
carbohydrates to short-chain fatty acids.
Increases in caecal acetate, butyrate
and propionate have been observed
with STAT
Robinson, 2010 [49] Mice Vancomycin Increases in the phyla Proteobacteria and
Tenericutes and the family Lactobacillaceae
Decrease in the family Lachnospiraceae
Membrez, 2008 [68] Mice (obese) Norﬂoxacin and ampicillin Decrease in aerobic and anaerobic bacteria Improved glucose tolerance
Looft, 2010 [69] Pigs Chlortetracycline–sulphamethazine
and penicillin
Increase in Proteobacteria, Escherichia coli
Kim, 2010 [70] Pigs Tylosin Lactobacillus and Sporacetigenum increased
Collier, 2003 [71] Pigs Tylosin Lactobacillus increased
Rettedal, 2009 [72] Pigs Chlortetracycline Lactobacillus amylovorus increased
Lactobacillus johnsonii decreased
Torok, 2011 [73] Chicken Avilamycin Lactobacillus crispatus, Lactobacillus reuteri,
Subdoligranulum and Enterobacteriaceae increased
Lachnospiraceae, Ruminococcaceae,
Oxalobacteraceae and L. johnsonii decreased
Torok, 2011 [74] Chicken Avilamycin L. crispatus, Lactobacillus salivarius,
Lactobacillus aviarus, Escherichia coli,
Bacteroides vulgatus or
Faecalibacterium prausnitzii increased
Improved feed conversion ratio as
measured by weight gain/amount of feed
consumed
Dumonceaux, 2006 [51] Chicken Virginiamycin Aerobic bacteria and Lactobacillus,
especially L. crispatus, increased
Guban, 2006 [75] Chicken Bacitracin L. salivarius decreased
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therapy [49], persistent effects have been described with some
antibiotics, such as quinolones and cefoperazone [49,52], and
recovery may sometimes be incomplete [53].
The inﬂuence of antibiotics on obesity
Moore et al. [54] ﬁrst discovered serendipitously in 1946 that
sulphonamide administration was associated with a two-fold
increase in weight in chicks fed adequate amounts of folic acid,
and he noted that the total gut bacterial count increased, with
coliform counts decreasing and lactobacilli increasing. Stokstad
et al. found that both Streptomyces aureofaciens and its bacte-
riocin, aureomycin, were associated weight gain, leading to the
proof-of-concept of the growth-promoting effect of both
probiotics and antibiotics [55,56]. Antibiotics, including mainly
tetracycline, glycopeptide, macrolides, and penicillin, have been
used for over 60 years to promote weight gain in animals [54],
with an optimal efﬁciency in pigs [57], and continue to be
widely used in the USA [58]. From the beginning of their use in
agriculture in the 1950s, a similar growth-promoting effect was
reported in humans [59–62], but this effect seems to have
been overlooked until recently [63–65].
Trasande et al. [65] found that exposure to antibiotics
during the ﬁrst 6 months of life is associated with consistent
increases in body mass. Exposures later in infancy (6–
14 months and 15–23 months) was not consistently associ-
ated with increased body mass. The authors concluded that,
although the effects of early exposure (<6 months) are modest
at the individual level, they could have substantial conse-
quences for population health. Many antibiotics have been
associated with weight gain in children and adults (Table 3).
Shortly after the ﬁrst animal studies, aureomycin (a tetracy-
cline) was shown to induce weight gain in preterm infants after
10 days [61]. Similar effects of tetracycline were reported in
premature infants, undernourished or rural children, young
recruits of the US navy, and patients with cystic ﬁbrosis and
pancreatic disease. Macrolides, which are widely used in the
animal industry, have been linked with human weight gain,
especially azithromycin in children with cystic ﬁbrosis in
double-blind randomized placebo-controlled studies (Table 2).
A recent meta-analysis conﬁrmed a signiﬁcant weight gain
effect of macrolides in patients with cystic ﬁbrosis [66].
Clarithromycin was associated with weight gain when used for
the eradication of Helicobacter pylori, with a link to acquired
obesity. Sulphonamides and co-trimoxazole have been linked
to weight gain when used as prophylaxis to prevent pneumonia
and other complications after measles in a community-based
randomized double-blind placebo-controlled trial in Guinea-
Bissau [67]. It is difﬁcult to conclude from these studiesT
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whether antibiotics are associated with weight gain through
their beneﬁcial effects in preventing or treating bacterial
infections, or through their effects on the microbiota. It is
plausible that a mixture of these two mechanisms is present in
different scenarios.
In summary, intriguing data link the microbiota composition
to metabolism, fat accumulation and obesity in animals and
people. Strangely, this was exploited long before the recog-
nition of the mechanism, through the use of probiotics and
antibiotics as growth promoters in animals. Figure 1 summa-
rizes the known data and mechanisms. More precise delinea-
tion of the mechanism might lead to tailored interventions or
preventive measures to combat one of the worst enemies of
humanity in the current millennium, obesity.
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